The company’s co-founders said they are leaving to start a new mRNA-based company.
Return to the 2022 stock-market playbook as Iran conflict drags on, say these strategists
Barclays says the chasm between winning and losing stocks in 2022 when Russia invaded Ukraine was huge. Here are their style picks.